Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis.

Bonelli, M; Ferner, E; Göschl, L; Blüml, S; Hladik, A; Karonitsch, T; Kiener, H P; Byrne, R; Niederreiter, B; Steiner, C W; Rath, E; Bergmann, M; Smolen, J S; Scheinecker, C

Bonelli, M; Ferner, E; Göschl, L; Blüml, S; Hladik, A; Karonitsch, T; Kiener, H P; Byrne, R; Niederreiter, B; Steiner, C W; Rath, E; Bergmann, M; Smolen, J S; Scheinecker, C.

Affiliation

Bonelli M; Medical University of Vienna, Vienna, Austria.

Arthritis Rheum ; 65(3): 599-607, 2013 Mar.

Article in En | MEDLINE | ID: mdl-23203906

Subject(s)

Arthritis, Rheumatoid/drug therapy; Arthritis, Rheumatoid/pathology; Cell Movement/drug effects; Immunoconjugates/therapeutic use; Monocytes/drug effects; Monocytes/pathology; Abatacept; Antigen-Presenting Cells/drug effects; Antigen-Presenting Cells/metabolism; Antigen-Presenting Cells/pathology; Antirheumatic Agents/therapeutic use; B7-1 Antigen/metabolism; B7-2 Antigen/metabolism; Cell Adhesion Molecules/metabolism; Female; Human Umbilical Vein Endothelial Cells; Humans; Lipopolysaccharide Receptors/metabolism; Male; Middle Aged; Monocytes/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Arthritis, Rheumatoid / Monocytes / Cell Movement / Immunoconjugates Limits: Female / Humans / Male / Middle aged Language: En Journal: Arthritis Rheum Year: 2013 Type: Article Affiliation country: Austria

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google